Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Megan Theissen"'
Autor:
Sabah Kadri, Jimmy Lee, Carrie Fitzpatrick, Natalie Galanina, Madina Sukhanova, Girish Venkataraman, Shruti Sharma, Brad Long, Kristin Petras, Megan Theissen, Mei Ming, Yuri Kobzev, Wenjun Kang, Ailin Guo, Weige Wang, Nifang Niu, Howard Weiner, Michael Thirman, Wendy Stock, Sonali M. Smith, Chadi Nabhan, Jeremy P. Segal, Pin Lu, Y. Lynn Wang
Publikováno v:
Blood Advances, Vol 1, Iss 12, Pp 715-727 (2017)
Abstract: Ibrutinib has generated remarkable responses in patients with chronic lymphocytic leukemia (CLL), including those with an unfavorable cytogenetic profile. However, patients develop resistance, with poor outcomes and no established treatment
Externí odkaz:
https://doaj.org/article/637796cbfd31417ebb804451e9532aa2
Autor:
Lia DeRoin, Marcela Cavalcante de Andrade Silva, Kristin Petras, Kelly Arndt, Nathaniel Phillips, Pankhuri Wanjari, Hari Prasanna Subramanian, David Montes, James McElherne, Megan Theissen, Renee Briese, Soma Das, Lucy A. Godley, Jeremy Segal, Daniela del Gaudio, Carrie Fitzpatrick, Jane E. Churpek
Publikováno v:
Human mutation. 43(7)
To avoid acquired variants found in the blood, cultured skin fibroblasts are a recommended DNA source for germline genetic testing in patients with hematologic disorders, but data are lacking regarding practicality and limitations. We conducted a ret
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd8b54613a3b8782046476304fbed562
https://pubmed.ncbi.nlm.nih.gov/35419889
https://pubmed.ncbi.nlm.nih.gov/35419889
Autor:
Jeremy P. Segal, Girish Venkataraman, Ailin Guo, Pin Lu, Kristin Petras, Y. Lynn Wang, Yuri Kobzev, Wenjun Kang, Weige Wang, Sonali M. Smith, Michael J. Thirman, Wendy Stock, Shruti Sharma, Natalie Galanina, Chadi Nabhan, Carrie Fitzpatrick, Howard L. Weiner, Madina Sukhanova, Sabah Kadri, Jimmy Lee, Nifang Niu, Megan Theissen, Brad Long, Mei Ming
Publikováno v:
Blood Advances. 1:715-727
Ibrutinib has generated remarkable responses in patients with chronic lymphocytic leukemia (CLL), including those with an unfavorable cytogenetic profile. However, patients develop resistance, with poor outcomes and no established treatment options.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::143c920f9d529f2c0b54b3fb117d2c2f
https://doi.org/10.1182/bloodadvances.2016003632
https://doi.org/10.1182/bloodadvances.2016003632
Autor:
Girish Venkataraman, Y. Lynn Wang, Weige V Wang, Bradley C. Long, Natalie Galanina, Shruti Sharma, Pin Lu, Megan Theissen, Howie Lawrence Weiner, Ailin Guo, Nifang Niu, Michael J. Thirman, Sabah Kadri, Carrie Fitzpatrick, Jimmy Lee, Madina Sukhanova, Jeremy P. Segal, Kang Wenjun, Mei Ming, Yuri Kobzev, Sonali M. Smith
Publikováno v:
Blood. 128:3961-3961
Introduction Ibrutinib (ibr), a first-in-class BTK inhibitor, has high response rates in both relapsed/refractory and treatment naïve chronic lymphocytic leukemia (CLL) independent of high-risk FISH abnormalities (NEJM. 2015; 373:2425-37, NEJM. 2013
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb5b3b5b35a2360e0c92abd953b39669
https://doi.org/10.1182/blood.v128.22.3961.3961
https://doi.org/10.1182/blood.v128.22.3961.3961